文献速递角膜与眼表疾病

芬戈莫德抑制干眼NOD小鼠模型核心恶性循环级联:涉及浸润白细胞中的1-磷酸鞘氨醇受体

Fingolimod Suppresses a Cascade of Core Vicious Cycle in Dry Eye NOD Mouse Model: Involvement of Sphingosine-1-Phosphate Receptors in Infiltrating Leukocytes.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究在干眼病NOD小鼠模型中评估芬戈莫德对浸润白细胞1-磷酸鞘氨醇受体(S1PRs)及细胞因子-基质金属蛋白酶(MMPs)/MAP激酶(MAPKs)信号通路的抑制作用。芬戈莫德滴眼显著抑制炎症介质和S1PRs表达,该效应可被W146逆转(P<0.01)。白细胞参与NOD小鼠干眼病,芬戈莫德治疗机制可能与通过浸润白细胞S1PRs抑制细胞因子-MMPs/MAPKs循环有关。

要点

  • 芬戈莫德滴眼显著抑制NOD干眼小鼠炎症介质和S1PRs表达,W146可显著逆转该效应(P<0.01)。
  • 双免疫荧光染色证实白细胞参与NOD小鼠干眼病。
  • 芬戈莫德治疗机制可能与通过浸润白细胞S1PRs抑制细胞因子-MMPs/MAPKs循环有关。

核心结论

  • 白细胞参与NOD小鼠干眼病;芬戈莫德治疗机制可能与通过浸润白细胞S1PRs抑制眼表组织中「细胞因子-MMPs/MAPKs」循环有关。

研究设计与样本

  • 研究使用64只雄性NOD小鼠(干眼病模型)和16只年龄匹配的BALB/c小鼠。
  • 预实验中16只NOD小鼠随机分为阳性对照组和芬戈莫德治疗组,8只BALB/c小鼠作为野生型对照。
  • 后续独立研究中48只NOD小鼠随机分为6组:三种浓度芬戈莫德治疗组(0.05%、0.005%、0.001%)、生理盐水组、未治疗组和芬戈莫德+W146组。
  • 动物接受生理盐水或芬戈莫德滴眼每日三次直至2个月后处死;芬戈莫德+W146组每日腹腔注射W146(0.1 mg/kg/天)。
  • 采用蛋白芯片检测促炎介质,酶谱法评估MMP-2和MMP-9活性,Western blot和免疫组化检测MAPKs和S1PRs。

主要发现

  • 在阳性对照组中,炎症介质和S1PRs水平上调。
  • 与阳性对照组相比,芬戈莫德治疗显著抑制这些标志物,而W146显著逆转该效应(P < 0.01)。
  • 双免疫荧光染色证实白细胞参与NOD小鼠模型中的干眼病。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose of this study was to evaluate the inhibitory mechanism of fingolimod and the involvement of sphingosine-1-phosphate receptors (S1PRs) and cytokines-matrix metalloproteinases (MMPs)/MAP kinases (MAPKs) signaling in a dry eye disease (DED) mouse model. METHODS: Sixty-four male NOD mice (DED model) and 16 age-matched BALB/c mice were used. In a preliminary experiment, 16 NOD mice were randomly divided into a positive control group and fingolimod-treated groups, with 8 BALB/c mice serving as wild-type control. In a subsequent, separate study, 48 NOD mice were randomly divided into 6 groups: fingolimod-treated groups at three different concentrations (0.05%, 0.005%, and 0.001%), normal saline group, untreated group, and fingolimod+W146 group. Animals received normal saline or fingolimod eyedrops three times daily until euthanasia 2 months later. Mice in the fingolimod+W146 group received daily intraperitoneal injections of W146 (0.1 mg/kg/day). Proinflammatory mediators were assessed by a protein array. Activities of MMP-2 and MMP-9 were evaluated by zymography. MAPKs and S1PRs were examined by Western blots and immunohistochemistry. Infiltrating cells and inhibitory mechanisms were assessed. RESULTS: In the positive control group, levels of inflammatory mediators and S1PRs were upregulated. By comparison, fingolimod treatment significantly suppressed such markers which were significantly reversed by W146 (P < 0.01). Importantly, by double immunofluorescence staining, leukocytes were confirmed involved in DED in the NOD mouse model. CONCLUSIONS: Leukocytes are involved in DED in the NOD mouse model. The therapeutic mechanisms of fingolimod may be associated with inhibitory roles of "cytokines-MMPs/MAPKs" cycle in NOD mouse ocular surface tissues by mediating S1PRs in infiltrating leukocytes.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Xiao W, Fu S, Xu K, et al. Fingolimod Suppresses a Cascade of Core Vicious Cycle in Dry Eye NOD Mouse Model: Involvement of Sphingosine-1-Phosphate Receptors in Infiltrating Leukocytes. Invest Ophthalmol Vis Sci. 2017. PMID: 29214311. doi:10.1167/iovs.17-21445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。